Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes mellitus is an increasingly common long-term condition, and suboptimal perioperative glycaemic control can lead to postoperative harms. The advent of new antidiabetic drugs, in particular glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors, has enabled perioperative continuation of these medicines, thus avoiding the harms of variable rate i.v. insulin infusions whilst providing glycaemic control. There are differences between medicines regulatory agencies and organisations on how these classes that are most often used to treat diabetes mellitus, (but also in the case of SGLT2 inhibitors chronic kidney disease and heart failure in those without diabetes) should be managed in the perioperative period. In this commentary, we argue that GLP-1 receptor agonists should continue during the perioperative period and that SGLT2 inhibitors should only be omitted the day prior to a planned procedure . The reasons for the differing advice advocated between regulatory agencies and what anaesthetic practitioners should do in the face of continuing uncertainty are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Dhatariya, K. K., Glaser, N. S., Codner, E., & Umpierrez, G. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0165-1 · Cited by 461
Self-citationEffect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., & Horowitz, M. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.07.003 · Cited by 261
Hamblin, P. S., Wong, R., Ekinci, E. I., Fourlanos, S., Shah, S., Jones, A. R., Hare, M. J. L., Calder, G. L., Epa, D. S., George, E. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00139 · Cited by 126
Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity
Jensterle, M., Ferjan, S., Ležaič, L., Sočan, A., Goričar, K., Zaletel, K., & Janez, A. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14944 · Cited by 102
Fayfman, M., Galindo, R. J., Rubin, D. J., Mize, D. L., Anzola, I., Urrutia, M. A., Ramos, C., Pasquel, F. J., Haw, J. S., Vellanki, P., et al. (2019) · Diabetes Care · doi:10.2337/dc18-1760 · Cited by 85
Jones, K. L., Rigda, R. S., Buttfield, M. D. M., Hatzinikolas, S., Pham, H. T., Marathe, C. S., Wu, T., Lange, K., Trahair, L. G., Rayner, C. K., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13633 · Cited by 66
Seki, H., Ideno, S., Shiga, T., Watanabe, H., Ono, M., Motoyasu, A., Noguchi, H., Kondo, K., Yoshikawa, T., Hoshijima, H., et al. (2023) · Journal of Anesthesia · doi:10.1007/s00540-023-03174-8 · Cited by 56
Cited by
El‐Boghdadly, K., Dhesi, J., Fabb, P., Levy, N., Lobo, D. N., McKechnie, A., Mustafa, O., Newland‐Jones, P., Patel, A., Pournaras, D. J., et al. (2025) · Anaesthesia · doi:10.1111/anae.16541 · Cited by 147
Self-citationGastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions
Jalleh, R. J., Rayner, C. K., Hausken, T., Jones, K. L., Camilleri, M., & Horowitz, M. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00188-2 · Cited by 144
Oprea, A. D., Ostapenko, L. J., Sweitzer, B., Selzer, A., Irizarry-Alvarado, J. M., Hurtado Andrade, M. D., Mendez, C. E., Kelley, K. D., Stewart, E., Fernandez Robles, C. R., et al. (2025) · British Journal of Anaesthesia · doi:10.1016/j.bja.2025.04.001 · Cited by 104
Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis
Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C., & Sun, E. C. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2024.7082 · Cited by 47
The peri‐operative implications of sodium‐glucose co‐transporter 2 inhibitors: a narrative review
Stewart, P. A., Nestor, C. C., Clancy, C., & Irwin, M. G. (2025) · Anaesthesia · doi:10.1111/anae.16461 · Cited by 16
Metadata
- Authors
- Dhatariya, K., Levy, N., Russon, K., Patel, A., Frank, C., Mustafa, O., Newland-Jones, P., Rayman, G., Tinsley, S., & Dhesi, J.
- Venue
- British Journal of Anaesthesia
- Publisher
- Elsevier BV
- Published
- 2024-04
- Volume
- 132
- Issue
- 4
- Pages
- 639-643
- ISSN
- 0007-0912 (ISSN-L)
- OpenAlex
- W4391303850
- Cited by
- 37
- References
- 12
- FWCI
- 10.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus. https://app.cochat.ai/papers/10.1016/j.bja.2023.12.015
- The paper
- Dhatariya, K., Levy, N., Russon, K., Patel, A., Frank, C., Mustafa, O., Newland-Jones, P., Rayman, G., Tinsley, S., & Dhesi, J. (2024). Perioperative use of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes mellitus. British Journal of Anaesthesia. https://doi.org/10.1016/j.bja.2023.12.015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.